Prasad, Gunari (2009) Cardiac Status of Long Term Survivors after Anthracycline Therapy. Masters thesis, Cancer Institute (WIA), Chennai.
|
Text
160703909prasadpgunari.pdf Download (307kB) | Preview |
Abstract
INTRODUCTION: Doxorubicin which belongs to the anthracycline family of drugs ,is a key component of Chemotherapy regimens and is the most active agent for the treatment of lymphoma. However doxorubicin use is limited by its severe cardiotoxicity, including Cardiomyopathy and congestive cardiac failure, which are late cardiac effects usually Occurring after doses greater than 550 mg/m2 (1).Early toxicity is rare and includes Myocarditis, pericarditis and arrhythmias .Late cardiotoxicity after doxorubicin has Largely been studied in children (2,3) but less often in adults. In children, the prinicipal risk Factor for anthracycline cardiomyopathy is highly dependant on cumulative doses (1-4). For Adults few studies have been performed in the setting of breast cancer with epirubicin (5) or Doxorubicin (6),of acute myeloid leukaemia after idarubicin (7)or after doxorubicin for Various hematologic malignancies (8,9).For these patients, an increased risk of developing Late cardiotoxicity after anthracycline treatment has been associated with advancing age Or with higher cumulative doses (4,9).Most of these studies involved patients who received Doxorubicin ranging from 450-550 mg/m2. Altough risk factors for doxorubicin –induced Congestive heart failure have been studied ,subclinical cardiac toxicity after lower doses of Doxorubicin is less usnderstood . Therefore we studied the occurrence of late cardiac abnormalities by measuring systolic Function, Left Ventricular Ejection Fraction (LVEF), Fractional shortening (FS) in Patients treated with doxorubicin for lymphoma .We evaluated the cardiac function of Patients observed for atleast 5 years after successful treatment of the lymphoma with Chemotherapy regimens including doxorubicin . AIMS OF THE STUDY 1. To assess the cardiac status of long term survivors who previously received doxorubicinbased Chemotherapy for lymphoma . 2. To analyze the risk factors for development of late anthracycline cardiotoxicity.
| Item Type: | Thesis (Masters) |
|---|---|
| Uncontrolled Keywords: | Cardiac Status ; Long Term Survivors ; Anthracycline Therapy. |
| Subjects: | MEDICAL > Medical Oncology |
| Depositing User: | Subramani R |
| Date Deposited: | 19 Aug 2017 03:41 |
| Last Modified: | 19 Aug 2017 03:41 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/2040 |
Actions (login required)
 |
View Item |
